# Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation

> **NCT01886248** · PHASE2 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 32 (estimated)

## Conditions studied

- Hepatic Veno-Occlusive Disease

## Interventions

- **DRUG:** Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU

## Key facts

- **NCT ID:** NCT01886248
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-06
- **Primary completion:** 2021-08
- **Final completion:** 2021-08
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01886248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01886248, "Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01886248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*